Related Experiment Videos
[Treatment of pneumonia acquired in the community]
T Waschbisch1, M Schlesser, R Nati
1Service de Pneumologie, Centre Hospitalier du Luxembourg, 4, rue Barblé, L-1210 Luxembourg.
Abstract:
The community-acquired pneumonia is a common and serious illness. Pneumonia is said to be community acquired if it is contracted outside of hospital environment or if it is diagnosed within the first 48 hours of hospitalisation. The pathogen remains unknown after investigations in around 50%. The patient should initially be treated empirically, based on the likely pathogens according to the patient's risk-factors, underlying diseases, severity of pneumonia and place of therapy. If recent guidelines are compared (American Thoracic Society, British Thoracic Society and the Infectious Disease Advisory Board) there are differences concerning epidemiology, patients classification and the empiric antibiotic treatment. The appearance of resistances and the recent availability of new antibiotics account partially for these differences. In order to avoid further resistances but still achieving an efficient treatment, coherent antibiotic schemes considering local microbiological epidemiology and patients classifications must be applied as proposed by different guidelines.
Insights
Community-acquired pneumonia (CAP) requires empirical antibiotic treatment. Guidelines vary, necessitating coherent antibiotic schemes based on local epidemiology and patient factors to combat resistance.
Area of Science:
- Infectious Diseases
- Microbiology
- Pulmonology
Context:
- Community-acquired pneumonia (CAP) is a significant global health concern.
- Identifying the causative pathogen in CAP is challenging, often remaining unknown in approximately 50% of cases.
- Empirical antibiotic treatment is standard for CAP, guided by patient risk factors, comorbidities, and disease severity.
Purpose:
- To analyze and compare current international guidelines for community-acquired pneumonia management.
- To highlight discrepancies in epidemiological data, patient classification, and empirical antibiotic strategies across different guidelines.
- To emphasize the need for updated antibiotic approaches considering antimicrobial resistance and new therapeutic options.
Summary:
- Empirical antibiotic selection for CAP depends on patient-specific factors and likely pathogens.
- Existing guidelines (e.g., ATS, BTS, IDAB) exhibit variations in managing CAP, influenced by evolving resistance patterns and new antibiotics.
- A unified approach integrating local microbiological data and patient stratification is crucial for effective CAP treatment and resistance mitigation.
Impact:
- Informed clinical decision-making for CAP treatment.
- Development of more consistent and effective antibiotic strategies globally.
- Potential reduction in antimicrobial resistance through optimized empirical therapy.